Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Use of Gocovri to Improve Disability Due to Radiation Encephalopathy | Clinical Trials | Clareo Health

Back to search

Not Yet RecruitingPhase 2

Use of Gocovri to Improve Disability Due to Radiation Encephalopathy

NCT07125222•Weill Medical College of Cornell University

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Radiation Encephalopathy

Interventions

Gocovri (extended-release amantidine)

Locations

United States

Locations (1)

Weill Cornell Medicine

New York, New York, United States

Key Dates

Start Date

September 1, 2025

Primary Completion Date

August 1, 2028

Completion Date

August 1, 2028

Last Updated

August 15, 2025

Contacts

Rajiv S Magge, MD

CONTACT

646-962-2185 ram9116@med.cornell.edu

Sponsors

Lead Sponsor

Weill Medical College of Cornell University

Collaborators

Supernus Pharmaceuticals

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 15, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions